Search

everythinglearnresearchcommunity

for

Search:↓

User restarted hair loss treatment with consistent finasteride, minoxidil, ketoconazole shampoo, and weekly dermarolling. Another user shared their regimen including dutasteride, oral minoxidil, RU58841, derma roller, ketoconazole shampoo, and stemoxydine.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.

The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.

A 54-year-old user shares progress after 3 years on dutasteride, following 15 years on finasteride, using 0.5 mg/day dutasteride, topical minoxidil every other day, and a peptide serum on alternate days. They experienced a significant shed during the transition but are now maintaining hair, noticing some new growth along the hairline.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.

The user is experiencing positive results in hair regrowth using a regimen of 0.5 mg dutasteride, 5 mg oral minoxidil, ketoconazole shampoo, microneedling, and a combination of topical minoxidil with RU58841. They report no side effects and express gratitude for the support and inspiration from the community.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

User shared progress on hair regrowth after 4 months of Spironolactone and iron infusions for Androgenic Alopecia. They see some improvement but struggle with perception; others note significant improvement.

The conversation is about a user's nearly 4-month hair loss treatment regimen, which includes dutasteride every other day, 0.25ml minoxidil on the hairline once a day, and using a 1.5 mm derma stamp every two weeks. Some responses question the need to start multiple treatments simultaneously, while others comment on the visible improvement and the necessity to continue treatment for sustained results.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

A 38-year-old user shared progress pictures after 3.5 months of using oral dutasteride, oral minoxidil, dermastamping, and Nizoral shampoo, reporting significant hair regrowth. The user is optimistic about further improvement, while others discuss the effectiveness and side effects of these treatments.

A user shared progress pictures after almost 3 months of using dutasteride, minoxidil, stemoxydine, and tretinoin for hair loss, reporting positive results and no significant side effects. The user chose dutasteride over finasteride due to early balding and noted benefits like better skin and increased libido.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

A 21-year-old male is experiencing crown balding and is using RU58841, topical minoxidil, and plans to add dutasteride and oral minoxidil to his treatment. He seeks advice on increasing his treatment stack despite previous side effects like chest pain.

The user experienced significant hair regrowth using finasteride, dutasteride, and oral minoxidil, noting improvements in eyebrows and eyelashes as well. Despite challenges, including a divorce and mental health struggles, the user is grateful for the progress and support from the community.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The user's progress with hair loss treatments of 0.5mg finasteride daily, minoxidil 5%, and nizoral 2%. They discuss if further growth is possible, their experience after two months, and encourage others to not lose hope.

The conversation discusses a 13-month hair loss treatment update using dutasteride, minoxidil, nizoral, and a 1.5mm derma roller, with the original poster reporting no side effects and some improvement in hair thickness. Participants request before-and-after pictures with consistent hairstyles to better assess the treatment's effectiveness.

User maintained hair with finasteride for 6 months, then switched to dutasteride for 7 months, using DHT blocking shampoo, keto 2% shampoo, and microneedling. Significant hair growth observed, especially on right temple.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

User sshamu's progress pictures of 4 months using minoxidil foam and 1MM dermarolling for hair loss, which resulted in impressive results. There is also discussion about how often to use the treatments, as well as potential side effects of finasteride.